Result of General Meeting

RNS Number : 9501H

Avacta Group PLC

23 May 2014

 



THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, NEW ZEALAND, JAPAN, THE REPUBLIC OF IRELAND OR THE REPUBLIC OF SOUTH AFRICA IN WHOLE OR IN PART, OR ANY JURISDICTION IN WHICH SUCH PUBLICATION OR DISTRIBUTION IS PROHIBITED. 

Avacta Group plc

("Avacta" or the "Group")

Result of General Meeting

Avacta Group plc (LSE: AVCT) a global provider of innovative diagnostic tools, consumables and reagents for human and animal healthcare, is pleased to announce that the Resolution put to shareholders at today's General Meeting in connection with the Placing announced by the Company on 7 May 2014, was duly passed.

Following the passing of the Resolution at the General Meeting, a total of 937,818,183 new Ordinary Shares, including 19,636,363 new Ordinary Shares allotted following the exercise of the Option by Numis Securities, have been allotted to existing and new investors, conditional upon the admission of such Ordinary Shares to trading on AIM.

It is expected that settlement will occur, admission to trading on AIM will become effective and dealings will commence in respect of 160,909,090 new Ordinary Shares, the VCT Shares, at 8.00am on 27 May 2014.

It is expected that settlement will occur, admission to trading on AIM will become effective and dealings will commence in respect of 776,909,093 new Ordinary Shares, the General Shares, at 8.00am on 28 May 2014.

Upon admission, both the VCT Shares and the General Shares will be issued, credited as fully paid and will rank pari passu in all respects with the existing Ordinary Shares of the Company.

Following admission of the 937,818,183 new Ordinary Shares to trading on AIM, the total number of Ordinary Shares with voting rights in issue will be 4,967,649,550 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

Capitalised terms in this announcement have the same meaning as in the circular sent to Shareholders in connection with the Placing on 7 May 2014.

For further information:

Avacta Group plc Alastair Smith, Chief Executive Officer Tim Sykes, Chief Financial Officer	Tel:  [phone] www.avacta.com
Numis Securities Limited     Michael Meade / Freddie Barnfield - Nominated Adviser James Black - Corporate Broking	Tel:  [phone] www.numiscorp.com
Media Enquiries Walbrook PR Ltd Mike Wort / Lianne Cawthorne	Tel: [phone] [e-mail]

About Avacta Group plc - www.avacta.com

Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. Avacta operates through three divisions:

Avacta Analytical www.avactaanalytical.com	High throughput analysis instrument, Optim, to help reduce the cost and risk of drug development.
Avacta Animal Health www.avactaanimalhealth.com	Veterinary diagnostics reference laboratory, diagnostic kits and newly launched in-clinic blood analyser, Sensipod.
Avacta Life Sciences www.avactalifesciences.com	Novel non-antibody affinity reagents called Affimers, with a wide range of Life Science applications in diagnostics, drug and biomarker discover and biotech research and development.

Avacta joined AIM in August 2006 and is based in Wetherby, England.

 

END

 

 

ROMUOSARSBAVUAR